Skye Bioscience, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Skye Bioscience terminated a material definitive agreement on September 8, 2026, and experienced a departure of director(s) or officer(s) with associated compensatory arrangement changes. Specific counterparty names, dollar amounts, share counts, and detailed terms of the termination are not disclosed in this 8-K header text; the full filing document would contain those details in Items 1.02 and 5.02.
Why this rating
Agreement termination and executive change are moderately material for a ~$130M company, but lack disclosed financial impact or strategic clarity in available text excerpt.
Extracted items
- 1.02 agreement termination
- 5.02 exec change
- 8.01 other event
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.